Background
==========

The transmissible spongiform encephalopathies (TSE) or prion diseases are fatal neurodegenerative disorders characterised by vacuolation, neuronal loss, gliosis and accumulation of an abnormal form (PrP^Sc^) of a natural host encoded \"prion\" protein (PrP^c^) \[[@B1]\].

Naturally occurring TSE are reported exclusively in mammals. Among non-human species they include scrapie in sheep and goats, chronic wasting disease in deer and elk, transmissible mink encephalopathy in farmed mink and bovine spongiform encephalopathy (BSE) in cattle and other species. BSE, initially diagnosed in Great Britain in domestic cattle \[[@B2]\]) and presenting as an extended common source epidemic, was shown to be transmitted via feeding commercial rations containing meat and bone meal (MBM) \[[@B3]\]. Unique among animal TSE, BSE was also transmitted via feed to several other captive bovid species \[[@B4]\] and through dietary inclusion of infected cattle tissues to a range of felids, both domestic \[[@B5]\] and zoo kept species \[[@B4]\]. Although the full extent of this species susceptibility to the BSE agent, which subsequently included humans \[[@B6]\], was not known in the early stages of the epidemic in cattle, the involvement of MBM as the primary vector of infection inevitably raised concerns regarding the potential infection of other domesticated livestock, including non-ruminant species \[[@B7],[@B8]\]. Ruminant-derived MBM was used as a component of domestic poultry rations until the United Kingdom ban on feeding mammalian MBM to all farm animals in April 1996 \[[@B9]\], providing oral exposure of this species to BSE infectivity at concentrations potentially similar to those promoting the bovine epidemic.

Neither at the time of the instigation of this study (June 1990) nor since, have there been published reports of naturally occurring avian TSE or successful transmission of a TSE to an avian species.

The present study examines the transmissibility of the BSE agent to domestic chickens by parenteral and oral routes of exposure. Transmission was initially evaluated on the basis of clinical monitoring of recipients for neurological disease, histopathological examinations for encephalopathic changes, and detection of aggregates of a proteinase K (PK) resistant form of the putative disease form (PrP^res^) of an avian prion protein (PrP^c^) in brain tissue, equivalent to scrapie-associated fibril (SAF) extraction in the diagnosis of mammalian prion diseases. Immunohistochemistry (IHC) for the detection of a disease specific form of the prion protein (PrP^d^) without the use of proteases was also attempted on brain using mammalian derived antibodies to PrP. In view of the empirical nature of this approach further work was undertaken to identify mammalian PrP antibodies that were most likely to detect avian PrP. In addition, Western immunoblotting for the detection of PrP^res^was undertaken similarly. Mouse bioassays for detection of tissue infectivity were also performed.

In the course of the primary transmission study a progressive neurological syndrome was observed in some male chickens of both parenteral and oral exposure groups without pathological evidence of a TSE. This syndrome was further investigated by sub-passage experiments.

Methods
=======

All procedures were carried out in accordance with the Animal (Scientific Procedures) Act 1986, under Licence from the UK Government Home Office (Licence numbers: 70/3994, 70/5257).

Inocula
-------

For the primary transmission study an inoculum was prepared as a 10% w/v homogenate, in saline, of pooled caudal medulla oblongata from two clinical BSE cases. These cases were confirmed by the statutory diagnostic methods in use at the time of their death in 1989: histopathological examination of the brain for spongiform encephalopathy and detection of SAF by negative-contrast transmission electron microscopy. Primary transmissions from brainstem of each of the donor cattle to inbred mice provided uniform disease characteristics consistent with the agent of BSE from previous sources (see cows 5 and 6 respectively from \[[@B10]\]). The uniformity of incubation periods obtained in the mice with those of the equivalent dilution of previously titrated inocula \[[@B11]\] suggested a titre for the present inoculum of 10^5^intracerebral ID~50~mouse infectious units per gram.

For the sub-passage experiments in chickens three inocula were prepared, all comprising a 10% w/v homogenate of pooled brain and sciatic nerve in saline. One inoculum pool was derived from all parenterally exposed chickens which exhibited the progressive neurological syndrome, the second from orally exposed chickens which exhibited the syndrome, and the third from clinically normal, saline inoculated control chickens. The same inocula pools were used for the inoculation of mice.

Animals and exposures
---------------------

Hybrid day old specific pathogen free (SPF) chicks were sourced for the study. For the primary transmission study 12 chicks were inoculated intracranially (i.c.) with 50 μl of the homogenate at 1 day old and then intraperitoneally (i.p.) with 1 ml at 2 weeks of age. To simulate the potential dietary exposure of domestic chicken to BSE contaminated feed, 11 chickens were inoculated with 5 g of pooled BSE affected brain tissue into the distal oesophagus/crop by gavage on 3 occasions, at 4, 5 and 6 weeks of age. This dose approximates to the average maximum daily intake of MBM at 15% incorporation into the diet for the first month of life. A further 14 chicks were inoculated i.c. with 50 μl of a 10% saline solution at 1 day old, then i.p. with 1 ml saline at 2 weeks of age and served as age matched controls for both the parenteral and oral primary exposure studies.

For the sub-passage experiments three groups of day-old SPF chicks were inoculated i.c. with 50 μl of each test inoculum. Fifteen received inoculum derived from parenterally exposed chickens exhibiting the neurological syndrome; sixteen received inoculum from orally exposed chickens exhibiting the syndrome and 13 received inoculum from clinically normal, saline inoculated control chickens. Twelve chicks were inoculated i.c. with saline only.

All chicks used in the primary exposure study were housed initially in experimental groups arranged as separate cage racks, with each cage containing an entire group. As the chicks grew the number per cage was reduced until, at approximately 4 months of age, they were housed singly. Chickens used in the sub-passage study were housed in a free range floor system.

Prior to the enforcement of the ban on feeding mammalian MBM to all farmed animals and for the first 4.5 months of the primary exposure, chicks were reared on a commercial diet containing a premixed MBM component (0.4% by weight) some of which may, in retrospect, have contained ruminant-derived protein. Thereafter the commercial ration was replaced with a home-mixed, MBM free ration which was fed *ad libitum*. For the sub-passage experiment all chickens were reared and maintained on the same home-mixed ration, fed *ad libitum*.

All chickens were monitored clinically for up to 5 years post inoculation (p.i.) when they were killed and examined post-mortem. Chickens developing intercurrent disease were killed if welfare was compromised.

Clinical monitoring
-------------------

The chickens were inspected daily for signs of abnormality by attendants at the time of husbandry duties, such as feeding and cleaning. In the primary study a veterinary clinician conducted a bi-weekly passive observation for 15 min per group. Any indications of abnormality were supported by an individual clinical examination that included testing of neurological reflexes and assessment of locomotion. These examinations were also conducted shortly before culling. Body weight, weekly food consumption and behaviour (time spent lying, standing, active, idle, preening or eating) were recorded. Weekly food consumption was recorded on four occasions. In the sub-passage study, the same methods were used but the passive clinical observations were conducted weekly.

Statistical analysis was performed using the Statistica package (version 10, Statsoft Ltd., Bedford, UK), which included analysis of variance of selected signs and survival analysis (chickens culled for welfare reasons were censored).

Post-mortem sampling
--------------------

From all chickens in the primary exposure study the frontal cerebrum, sciatic nerve, skeletal muscles (pectoral and hindlimb adductors), liver, spleen, kidney, small intestine and bursa of Fabricius were aseptically sampled and stored frozen for possible subsequent bioassay studies. A segment of cervical spinal cord was taken for SAF extraction and stored at -20°C. The brain, spinal cord, sciatic nerve, pectoral and adductor muscles and bursa of Fabricius were also sampled for histopathological and immunohistochemical examinations. Additional tissues were sampled as gross post-mortem findings required, particularly where initial observations indicated changes potentially causal in intercurrent disease deaths. Central nervous system tissue was placed into 10% formol saline and other tissues were fixed in neutral buffered 10% formalin. After post-mortem removal of the cervical spinal cord segment the remaining spinal cord was fixed in situ within the vertebral canal to avoid possible fresh dissection damage to the cord and was later removed for further sampling. Chickens which died or were killed because of intercurrent disease before the planned termination of the study were examined similarly.

From all chickens in the sub-passage study, selected fresh tissues were aseptically sampled post-mortem, including frontal cerebrum, cervical and thoracic spinal cord, sciatic nerve, pectoral muscle, adductor muscle, ischiotibial muscle, heart, liver, spleen, kidney, small intestine, and bursa of Fabricius. The range of tissues sampled for histopathological examination encompassed those for the primary exposure study. Chickens that died or were killed because of intercurrent disease before the planned kill date were examined similarly.

Histopathology
--------------

Blocks were prepared from coronal sections of the brain at eight levels, approximating to selected levels from an atlas of the chicken brain (levels 9,10,12,14,17,19, 23 and 24, see \[[@B12]\]) to achieve representation of all major brain regions. Transverse blocks of spinal cord (cervical, thoracic and lumbar) were also prepared. Sciatic nerve and skeletal muscles were blocked transversely and longitudinally. Visceral tissue samples were blocked routinely.

Tissues were fixed for 3-5 days and then processed overnight on an automatic tissue processor before embedding in paraffin wax. Sections 5 μm thick were cut and stained by a modification of the routine haematoxylin and eosin method \[[@B13]\]. Muscles were stained using a collagen and elastin method.

SAF examination
---------------

Cervical spinal cord samples were prepared for SAF examination by an extraction technique as described previously \[[@B14],[@B15]\]. The resulting negatively stained samples were examined in either a Phillips 410 or a CM10 transmission electron microscope at magnifications greater than 25,000. A positive result was recorded if one or more fibrils within the original definition \[[@B16]\] were identified. Where fibrils were not detected each sample was examined for 20 min before being declared negative. Thirty-three samples from the primary exposure study were examined: 10/12 parenterally exposed chickens, 11/11 orally exposed chickens, and 12/14 control chickens. Thirty-six samples from the sub-passage study were examined similarly: 14/15 chickens inoculated with nervous tissue from parenterally exposed chickens in the primary exposure study, 10/16 chickens inoculated with nervous tissue from orally exposed chickens, and 12/13 chickens inoculated with nervous tissue from saline controls.

Immunohistochemistry
--------------------

A series of IHC examinations were carried out on central nervous system tissues for the detection of a putative disease form of an avian prion protein. Interpretation of immunodetection was necessarily made without the benefit of an avian TSE/prion disease positive control. Controls included BSE affected bovine brainstem, BSE and scrapie affected sheep brainstem, omission of the primary antibody, substitution of the primary antibody with normal rabbit serum or immunoglobulin (Ig) G from the species in which each antibody was raised, and brainstem from normal cattle and sheep.

Initially, frontal cerebrum, cerebellum/medulla and spinal cord from one control (ID: 962) and one orally exposed (ID: 976) chicken from the primary exposure study were immunolabelled with antibodies IA8 and 971 F (Table [1](#T1){ref-type="table"}). Subsequently, the same tissues from up to three chickens per treatment group (ID: 379, 390, 715, 853, 866, 928, 929, 946) in the sub-passage study were immunolabelled with antibodies 1B3, F99, IA8, L42, R145 and Rb486 (Table [1](#T1){ref-type="table"}).

###### 

PrP antibodies used for immunohistochemistry

  Antibody   Mono/Polyclonal   Immunogen raised against                                     Dilution            Reference
  ---------- ----------------- ------------------------------------------------------------ ------------------- -------------------
  1B3        Polyclonal        Mouse ME7 scrapie SAF                                        1/1000              \[[@B17],[@B18]\]
                                                                                                                
  IA8        Polyclonal        Mouse ME7 scrapie SAF                                        1/2500              \[[@B17]\]
                                                                                                                
  971F       Polyclonal        Bovine PrP 221-232                                           1/2500              \[[@B18]\]
                                                                                                                
  F99        Monoclonal        Ovine PrP 220-225                                            1/4000 and 1/8000   \[[@B19]\]
                                                                                                                
  P4         Monoclonal        Ovine PrP 89-104                                             1/12000             \[[@B20]\]
                                                                                                                
  R145       Monoclonal        Bovine PrP 221-232                                           1/100 and 1/500     \[[@B21]\]
                                                                                                                
  L42        Monoclonal        Ovine PrP 145-163                                            1/250               \[[@B22]\]
                                                                                                                
  Rb486      Polyclonal        Bovine PrP 240-254                                           1/2500              \[[@B22]\]
                                                                                                                
  R568       Polyclonal        Ovine PrP 126-143                                            1/100               \[[@B23]\]
                                                                                                                
  6 C2       Monoclonal        Ovine PrP 114-120                                            1/100               \[[@B24]\]
                                                                                                                
  2 G11      Monoclonal        Ovine PrP 146-R^154^R^171^-182 (recognising R^151^-R^159^)   1/400               \[[@B25]\]

Investigations were also carried out which aimed to maximise the chances of detecting PrP^d^. First, brain blocks from both the primary exposure and sub-passage studies were selected in which mild vacuolar changes had been detected. Secondly, since there are currently no commercially available antibodies raised against the chicken prion protein, epitope sequences for 24 ovine and bovine anti-PrP antibodies were aligned to the National Center for Biotechnology Information (NCBI) reference sequence for the chicken prion protein (NP_990796.1) to select potentially appropriate antibodies. Alignments were performed using the European Bioinformatics Institute European Molecular Biology Open Software Suite (EBI EMBOSS) pairwise alignment algorithms \[[@B26]\] with a gap penalty of 25 to ensure full-length matches. For each alignment the percent identity and percent similarity to the full-length of the epitope sequence was calculated. Two antibodies (R568 and 6 C2) were identified which had 100% identity to epitopes on the chicken prion protein. These antibodies were then used in further IHC examinations in parallel with antibodies R145, 2 G11 and P4.

Brain samples from six exposed chickens, which had displayed neurological signs and which had the longest survival times in their treatment group (ID: 388, 963, 972, 985, 977, 990) (Table [2](#T2){ref-type="table"}), were selected for IHC examination. For two of the chickens (ID: 977, 990) for which both fixed and frozen brain was available, Western immunoblotting examinations were also conducted (see below). Brains samples from two healthy unexposed chickens were included as negative controls.

###### 

Individual data for chickens in primary exposure study

  Bird Identification   Inoculum     Route of exposure   Sex   Survival time (days)   **Experimental outcome (E/D)**^**a**^**and occurrence of syndromes (M/N)**^**b**^
  --------------------- ------------ ------------------- ----- ---------------------- -----------------------------------------------------------------------------------
  986                   Bovine BSE   Parenteral^c^       f     65                     \(E\) Neurological signs, NSL
                                                                                      
  988                   Bovine BSE   Parenteral          f     273                    (D)/NSL
                                                                                      
  982                   Bovine BSE   Parenteral          m     274                    (D)/NSL
                                                                                      
  981                   Bovine BSE   Parenteral          f     378                    \(E\) Egg peritonitis
                                                                                      
  983^d^                Bovine BSE   Parenteral          m     664                    \(E\) Acute onset (M)
                                                                                      
  980^d^                Bovine BSE   Parenteral          m     1302                   (D)/NSL (M/N)
                                                                                      
  984^d^                Bovine BSE   Parenteral          m     1486                   (D)/NSL (M)
                                                                                      
  989                   Bovine BSE   Parenteral          f     1780                   \(D\) Ovarian adenocarcinoma (N)
                                                                                      
  979                   Bovine BSE   Parenteral          f     1804                   \(E\) Ovarian adenocarcinoma (N)
                                                                                      
  987                   Bovine BSE   Parenteral          f     1841                   Terminal kill/NSL (M/N)
                                                                                      
  985^§^                Bovine BSE   Parenteral          m     1841                   Terminal kill/NSL (M/N)
                                                                                      
  990                   Bovine BSE   Parenteral          f     1843                   Terminal kill/NSL (M/N)
                                                                                      
  966                   Bovine BSE   Oral                f     390                    \(E\) Hepatitis
                                                                                      
  970                   Bovine BSE   Oral                f     573                    \(E\) Weight loss
                                                                                      
  976^d^                Bovine BSE   Oral                m     1230                   \(E\) (M)
                                                                                      
  978^d^                Bovine BSE   Oral                m     1413                   \(E\) (M)
                                                                                      
  969^d^                Bovine BSE   Oral                m     1555                   \(E\) Collapse (M)
                                                                                      
  965^d^                Bovine BSE   Oral                m     1601                   \(E\) (M)
                                                                                      
  967                   Bovine BSE   Oral                f     1808                   \(D\) Ovarian adenocarcinoma
                                                                                      
  971                   Bovine BSE   Oral                f     1830                   Terminal kill/NSL (N)
                                                                                      
  968                   Bovine BSE   Oral                f     1830                   Terminal kill/NSL (N)
                                                                                      
  977                   Bovine BSE   Oral                m     1834                   Terminal kill/NSL (M)
                                                                                      
  972                   Bovine BSE   Oral                f     1834                   Terminal kill/NSL (N)
                                                                                      
  959                   Saline       Parenteral          f     222                    \(D\)
                                                                                      
  958                   Saline       Parenteral          m     395                    \(E\) Weight loss
                                                                                      
  955                   Saline       Parenteral          m     757                    \(D\)
                                                                                      
  960                   Saline       Parenteral          m     862                    \(E\) Weight loss/NSL
                                                                                      
  956                   Saline       Parenteral          m     1037                   (D)/NSL
                                                                                      
  964                   Saline       Parenteral          m     1037                   \(E\) Neurological signs/NSL
                                                                                      
  951                   Saline       Parenteral          m     1225                   \(E\) Neurological signs/NSL
                                                                                      
  961                   Saline       Parenteral          f     1310                   \(E\) Egg peritonitis
                                                                                      
  954                   Saline       Parenteral          f     1528                   \(E\) Weight loss/NSL
                                                                                      
  963                   Saline       Parenteral          f     1547                   \(D\) Ovarian adenocarcinoma (N)
                                                                                      
  953^b^                Saline       Parenteral          m     1837                   \(D\) Meningoencephalitis (N)
                                                                                      
  952^b^                Saline       Parenteral          f     1868                   Terminal kill/NSL
                                                                                      
  962^b^                Saline       Parenteral          f     1868                   Terminal kill/NSL (N)
                                                                                      
  957^b^                Saline       Parenteral          f     1868                   Terminal kill/splenomegaly/meningo-encephalitis (N)

*m*male; *f*female

^a^*E*euthanasia due to compromised welfare; *D*found dead

^b^*M*motor disturbance syndrome; *N*narcolepsy

^c^intracranial and intraperitoneal

*NSL*no significant lesions at necropsy

^d^Donor chicken for sub-passage studies

Western immunoblotting (WB)
---------------------------

For the detection of PrP^res^by WB in brain tissue, from one orally exposed (ID: 977), one intracerebrally inoculated (ID: 990) (from the primary inoculation experiment) and two healthy non-exposed chickens, the commercially available BioRad TeSeE™ Western blot (BioRad, Marnes le Coquette, France) was used according to manufacturers instructions with a minor change. The test was modified by replacing the kit primary antibody with monoclonal antibody 6C2 \[[@B24]\]. No avian BSE-positive control tissue was available for profile comparison but two brain samples from healthy, non-inoculated chickens were included as negative controls.

Mouse bioassays for detection of infectivity
--------------------------------------------

Three pooled inocula comprising brain and sciatic nerve from selected primary parenterally inoculated (ID: 980, 983, 984, 985), orally inoculated (ID: 965, 969, 976, 978) and saline inoculated control (ID: 952, 953, 957, 962) chickens respectively (Table [2](#T2){ref-type="table"}), were assayed in a panel of five inbred mouse strains (Rlll (Sinc^s7^), C57BLJ6 (Sinc^s7^), VM (Sinc^p7^), IM (Sinc^p7^) and an F1 cross of C57BLJ6 and VM) according to standard procedures \[[@B10]\]. Using 20 mice per strain group, each mouse was injected with 0.02 ml i.c. and 0.1 ml i.p. of a single inoculum. Mice were clinically monitored from 250 days p.i. and the clinical end-point, when the mice showed clear clinical signs of neurological disease, was determined according to established criteria for calculating incubation period \[[@B27]\]. End points for termination of assays were 900 days for the RIII, VM and IM mice, 950 days for C57BL mice, and 800 days for the F1 cross mice. Mice surviving to these end-points were killed and their brains removed and processed routinely for histopathological examination for evidence of a TSE-like encephalopathy and immunohistochemical examination for PrP^d^using rabbit antiserum Rb486 as described previously \[[@B28]\]. Mice which died or were killed because of intercurrent disease before the end point were examined similarly.

Results
=======

Individual animal results of the primary and sub-passage transmission experiments are given in Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}.

###### 

Individual data for recipient chickens in sub-passage study

  Bird identification   Primary exposure group source of inoculum   Sex   Survival time (days)   **Experimental outcome (E/D)**^**b**^
  --------------------- ------------------------------------------- ----- ---------------------- ---------------------------------------------------------------------
  387                   Parenteral BSE                              m     111                    \(E\) Pecking trauma
                                                                                                 
  391                   Parenteral BSE                              f     131                    \(E\) Neurological signs/NSL
                                                                                                 
  392                   Parenteral BSE                              f     353                    \(E\) Prolapsed oviduct
                                                                                                 
  385                   Parenteral BSE                              m     916                    \(E\) Neurological signs/NSL
                                                                                                 
  384                   Parenteral BSE                              m     1059                   \(D\) Pneumonia
                                                                                                 
  390                   Parenteral BSE                              f     1217                   \(E\) Ovarian adenocarcinoma
                                                                                                 
  393                   Parenteral BSE                              f     1229                   \(E\) Ovarian adenocarcinoma
                                                                                                 
  395                   Parenteral BSE                              f     1266                   \(E\) Ovarian adenocarcinoma
                                                                                                 
  379                   Parenteral BSE                              m     1377                   \(E\) Neurological signs/NSL
                                                                                                 
  394                   Parenteral BSE                              f     1728                   \(D\) Ovarian adenocarcinoma
                                                                                                 
  389                   Parenteral BSE                              f     1728                   \(E\) Ovarian adenocarcinoma
                                                                                                 
  376                   Parenteral BSE                              m     1834                   Terminal kill/NSL
                                                                                                 
  378                   Parenteral BSE                              m     1834                   Terminal kill/NSL
                                                                                                 
  382                   Parenteral BSE                              m     1834                   Terminal kill/NSL
                                                                                                 
  388                   Parenteral BSE                              m     1834                   Terminal kill/NSL
                                                                                                 
  945                   Oral BSE                                    f     154                    \(E\) Pecking injuries
                                                                                                 
  943                   Oral BSE                                    f     209                    \(E\) Pecking injuries
                                                                                                 
  930                   Oral BSE                                    m     353                    \(E\) Crop impaction
                                                                                                 
  931                   Oral BSE                                    m     353                    \(E\) Crop impaction
                                                                                                 
  942                   Oral BSE                                    f     448                    \(E\) Egg peritonitis
                                                                                                 
  928                   Oral BSE                                    m     891                    \(E\) Musculoskeletal/neurological signs
                                                                                                 
  935                   Oral BSE                                    f     940                    \(E\) Wing fracture
                                                                                                 
  937                   Oral BSE                                    f     951                    \(E\) Musculoskeletal/neurological signs
                                                                                                 
  929                   Oral BSE                                    m     967                    \(E\) Neurological signs
                                                                                                 
  927                   Oral BSE                                    m     1258                   \(D\) Previous neurological signs.
                                                                                                 
  946                   Oral BSE                                    f     1483                   \(E\) Egg peritonitis
                                                                                                 
  939                   Oral BSE                                    f     1636                   \(D\) Ovarian adenocarcinoma
                                                                                                 
  933                   Oral BSE                                    m     1833                   Terminal kill/degenerative joint disease
                                                                                                 
  941                   Oral BSE                                    m     1833                   Terminal kill/degenerative joint disease
                                                                                                 
  936                   Oral BSE                                    f     1833                   Terminal kill/mild egg peritonitis
                                                                                                 
  926                   Oral BSE                                    m     1833                   Terminal kill/degenerative joint disease
                                                                                                 
  870                   Parenteral saline control                   f     156                    \(E\) Prolapsed oviduct
                                                                                                 
  860                   Parenteral saline control                   f     209                    \(E\) Pecking trauma
                                                                                                 
  865                   Parenteral saline control                   m     328                    \(E\) Crop impaction
                                                                                                 
  858                   Parenteral saline control                   m     513                    \(E\) Suppurative keratitis
                                                                                                 
  862                   Parenteral saline control                   m     1206                   \(D\) Possible ataxia/NSL
                                                                                                 
  853                   Parenteral saline control                   m     1219                   \(E\) Neurological signs/NSL
                                                                                                 
  866                   Parenteral saline control                   m     1343                   \(E\) Musculoskeletal/neurological signs/NSL
                                                                                                 
  856                   Parenteral saline control                   f     1372                   \(E\) Neurological signs/NSL
                                                                                                 
  851                   Parenteral saline control                   m     1620                   \(D\) Possible neurological signs/NSL
                                                                                                 
  855                   Parenteral saline control                   m     1643                   \(D\) Musculoskeletal/neurological signs/NSL
                                                                                                 
  863                   Parenteral saline control                   m     1655                   \(E\) Musculoskeletal/neurological signs/degenerative joint disease
                                                                                                 
  871                   Parenteral saline control                   f     1666                   \(D\) Ovarian adenocarcinoma
                                                                                                 
  867                   Parenteral saline control                   f     1835                   Terminal kill/degenerative joint disease
                                                                                                 
  710                   Saline^a^                                   m     351                    \(E\) Musculoskeletal/neurological signs.
                                                                                                 
  704                   Saline^a^                                   f     446                    \(E\) Prolapsed oviduct
                                                                                                 
  712                   Saline^a^                                   m     730                    \(E\) Intermittent haemorrhage from comb
                                                                                                 
  708                   Saline^a^                                   f     761                    \(E\) Coelomic mass
                                                                                                 
  715                   Saline^a^                                   m     968                    \(E\) Neurological signs
                                                                                                 
  707                   Saline^a^                                   f     1439                   (D)Ovarian adenocarcinoma
                                                                                                 
  706                   Saline^a^                                   f     1448                   \(E\) Ovarian adenocarcinoma
                                                                                                 
  705                   Saline^a^                                   f     1721                   \(E\) Egg peritonitis
                                                                                                 
  714                   Saline^a^                                   m     1729                   Terminal kill/multifocal non-suppurative meningoencephalitis
                                                                                                 
  709                   Saline^a^                                   m     1729                   Terminal kill/NSL
                                                                                                 
  711                   Saline^a^                                   m     1730                   Terminal kill/NSL
                                                                                                 
  713                   Saline^a^                                   m     1730                   Terminal kill/NSL

All recipient chickens were exposed intracranially

^a^Saline controls, not derived from primary transmission groups

*m*male; *f*female

^b^*E*euthanasia due to compromised welfare; *D*found dead

*NSL*no significant lesions at necropsy

Survival analysis
-----------------

Of the 93 chickens in the study 72 (77.42%) were included in the Kaplan-Meier survival analysis while 21 (22.58%) were censored. No significant difference was detected between treatment groups in the primary exposed (*P*= 0.34) (Figure [1](#F1){ref-type="fig"}) or sub-passage (*P*= 0.79) (Figure [2](#F2){ref-type="fig"}) experiments. Overall, the survival times for the primary exposure and sub-passage groups were not significantly different (*P*= 0.74).

![**Kaplan-Meier survival data for primary exposure study**. Survival data is shown for chickens challenged with BSE parenterally (*orange*), orally (*blue*) and the saline-challenged control group (*black*).](1756-0500-4-501-1){#F1}

![**Kaplan-Meier survival data for sub-passage study**. Survival data is shown for chickens challenged intracranially with inoculum made from parenterally (*orange*), orally (*blue*) BSE-challenged chickens exhibiting the neurological syndrome, from clinically normal saline-challenged control chickens (*black*) of the primary exposure study and a separate intracranially saline-challenged control group (*grey*).](1756-0500-4-501-2){#F2}

Clinical assessments
--------------------

A number of chickens were lost to intercurrent diseases which included ovarian adenocarcinoma, sometimes with transcoelomic metastases and egg peritonitis in female chickens. Impaction of the crop also occurred. Degenerative joint disease featured in a proportion of long-surviving chickens. These disorders did not manifest with neurological signs and occurred in exposed and control chickens in both the primary and sub-passage experiments (Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}).

Body weight and behavioural observations were analysed using analysis of variance with treatment group and sex as factors. The males were found to be significantly heavier than the females (*P*\< 0.05) but no significant differences between treatment groups were detected. On the last of the weekly occasions when food consumption was recorded, a highly significant (*P*\< 0.05) treatment effect was found. In this week the parentally and orally exposed chickens ate significantly less than the controls, 28% and 37% respectively. No significant treatment effects were found on the specific behavioural features recorded but it was apparent that males spent significantly more time idle compared with females.

Two clinical neurological syndromes were recognised in the primary experiments. First, a syndrome associated with feeding: chickens would appear to develop an episodic loss of consciousness resembling narcolepsy. This occurred in both exposed and control chickens. More female chickens displayed this behaviour than males (Table [4](#T4){ref-type="table"}) and the episodes in females tended to be more pronounced than those displayed by male chickens.

###### 

Incidence of cases of feeding-associated narcolepsy and motor disturbance syndrome (MDS) by sex

                         **Narcolepsy**^**a**^   **MDS**^**a**^           
  ---------------------- ----------------------- ---------------- ------- -------
  **Treatment group**    **m**                   **f**            **m**   **f**
                                                                          
  Parenterally exposed   2/3                     4/4              4/4     0/4
                                                                          
  Orally exposed         0/1                     3/3              5/5     0/4
                                                                          
  Control                1/1                     5/6              0/5     0/6

*m*male; *f*female

^a^Number of chickens affected/number of chickens surviving at the time of onset of the syndrome

The signs observed were evident during a period of feeding activity (sometimes this may have been simulated or \"sham feeding\") when affected chickens would appear to become semi-conscious, slowly adopting sternal and then lateral recumbency. They then remained still, apart from occasional weak wing or leg movements, for up to three minutes before suddenly and spontaneously regaining full consciousness. On recovery from an episode, affected chickens would often resume feeding immediately, a practice that then appeared to evoke repetition of the syndrome (see additional file [1](#S1){ref-type="supplementary-material"}: 979 NS, which shows one of these episodes during feeding).

Secondly, a motor disturbance syndrome (MDS) was observed in four parenterally exposed and four orally exposed male chickens. None of the female exposed or control chickens that survived to the terminal kill developed the syndrome (Table [4](#T4){ref-type="table"}).The first case (ID: 983) presented at 1,302 days p.i. and others subsequent through to the terminal kill at 1,834 days p.i. In seven of the chickens the disorder was slowly progressive, while in one chicken there was an acute onset of clinical signs (ID: 983). Clinical signs associated with the disorder variably included: ataxia, deficits in righting reflexes, balance deficits, tremor, abduction of the leg to maintain standing posture, voice change, immobility, tendency to sternal and/or lateral recumbency, partial closing of the eyelids, and rapid dilatation and constriction of the pupil (see additional file [2](#S2){ref-type="supplementary-material"}: 980 MDS, which shows a chicken with balance deficits).

In the sub-passage experimental groups a number of chickens in all groups were lost to a similar range of intercurrent diseases as in the primary exposure experiment and these occurred to a similar extent in exposed and control chickens.

A number of chickens also developed a range of neurological signs including ventroflexion of the neck, abnormal head movements, ataxia, balance deficits, depressed mentation and weakness/collapse, resembling some aspects of the MDS, but the narcolepsy-like syndrome was not observed.

Histopathology
--------------

Overall, no significant or systematic degenerative pathology was identified in the brain, spinal cord, sciatic nerve or skeletal muscle tissues of any of the chickens. Relatively sparse multiple large vacuoles were observed in the superficial grey matter of the optic tectum, white matter tracts of the brainstem and cerebellar white matter of both control and exposed chickens. Vacuolar change was also often seen in the spinal cord grey matter but occurred in both control and exposed chickens.

SAF examination
---------------

No TSE associated fibrils could be detected in any of the spinal cords from inoculated or control chickens from which material was examined.

Immunohistochemistry
--------------------

Each antibody tested showed patterns of particulate or diffuse immunolabelling, but similar patterns and intensities of labelling for individual antibodies occurred in both control and BSE exposed chickens. For example, R486 immunolabelled multi-focal neuropil areas in the spinal central grey matter, R586 showed diffuse high background immunolabelling with intense labeling of neuronal perikarya and neuropil of some strata. With other antibodies including R145 the predominant labelling was a widespread fine particulate form. Similar labelling was observed with antibody 6C2 and remained in tissue sections where the primary antibody (6C2) was omitted or replaced with mouse IgG.

IA8 also immunolabelled the spinal dorsal horn grey matter and spinal ganglia perikarya and IB3 and L42 immunolabelled populations of neurons.

Western immunoblotting
----------------------

Protein bands were detected by mAb 6C2 in the non-PK treated chicken samples as well as the known positive bovine BSE and ovine scrapie control samples, however the molecular mass of the bands detected in the chicken samples was too great to be compatible with the sequence-based estimate for chicken PrP. Following PK digestion, PrP^res^was only detected in the positive BSE and scrapie control samples and not in samples from inoculated or non-inoculated chickens.

Mouse bioassay
--------------

There was no confirmatory evidence of infectivity in any of the pools. A number of mouse brains showed vacuolar changes, e.g. in the corpus callosum, which are commonly seen in aged wild-type mice \[[@B29]\].

Discussion
==========

No evidence of the susceptibility of chickens to BSE emerged from these primary inoculation or sub-passage experiments. Kaplan-Meier survival data showed no significant differences between control and treatment groups. No pathology, which in mammals would have significance in relation to TSE, was identified in any of the chickens. Although there have been no substantiated reports of naturally occurring avian prion disease, Schoon et al. \[[@B30]\] described three cases of interest in red-necked ostriches (*Struthio camelus*) in two zoos in northern Germany, in 1986, 1988 and 1989. These birds, and two subsequent cases in 1992-1993, displayed progressive clinical signs of a nervous disorder with ataxia, changes to balance, uncoordinated movements during feeding and had vacuolar changes in the brainstem, but transmission studies failed to establish the nature of the disorder \[[@B31]\].

The two clinically defined syndromes observed in the present study appear to be more of interest in terms of the husbandry and experimental circumstances than of significance to the study aims.

The narcolepsy-like behaviour seemed to be associated with the approach of food satiety, but the behaviour was not observed in the sub-passage study when the housing was a free range floor system, suggesting that prolonged cage confinement in the primary study may have played a role.

Although in the primary study the MDS was observed only in exposed chickens, insufficient male control chickens survived to the terminal kill to determine whether there was a statistically significant correlation between exposure to BSE and the development of MDS, or whether MDS was a disorder peculiar to the males of the strain of chicken used in the experiment.

Similar signs to those of the MDS observed in the primary exposure study also occurred in each group in the sub-passage study, but the more frequent occurrence of such cases in the chickens that received tissues from the saline control chickens of the primary study than recipients of tissues from BSE exposed chickens, argues strongly against any relationship to exposure to the BSE agent.

Neither the feeding associated narcolepsy nor MDS have previously been reported in commercially farmed domestic chickens. However, these syndromes were observed in circumstances that were themselves unusual. The lifespan of commercially farmed chickens is usually approximately 45 days (broiler chickens) to 18 months (laying chickens) and their behaviour is not scrutinized in detail. Since neither of the syndromes or any other intercurrent diseases were observed in chickens less than 2 years of age it is possible that the observed behavioural abnormalities could be inherent to this strain of chickens without having been reported previously.

No lesions were observed in the central or peripheral nervous system that were significant either in terms of transmission of BSE or the clinical neurological signs observed. The vacuolation observed in the central nervous system of both the chickens and mice is most probably age and or host strain related.

Using biochemical extraction and PK digestion techniques, identical or similar to the one used in this study, SAF have been detected in a wide range of prion diseases, both natural and experimental \[[@B2],[@B5],[@B16],[@B32]-[@B41]\]. SAF are considered to be aggregates of the abnormal prion protein and, prior to the routine introduction of immunochemical methods for the detection of the protein, were the most studied pathological marker for the TSE \[[@B42]\]. The detection of SAF in the diagnosis of mammalian TSE has been shown to be a relatively insensitive approach but unlike immunochemical methods, provides morphologic detection of the extracted altered protein, independent of the problems of specificity of immunochemical detection in a species for which reagents and appropriate control materials are lacking. Therefore, not withstanding sensitivity issues, negative results by this method in the present study might be considered to give more definitive information on the absence of significant accumulations of an altered form of the prion protein in central nervous tissue.

No disease-specific immunolabelling was seen with any of the antibodies used, including 6C2 and R568. The widespread punctate immunolabelling observed appear related to technical factors which are largely irresolvable in the absence of species and disease specific antibodies, positive control material and appropriately developed epitope demasking procedures.

In the present study mammalian derived PrP antibodies were not able to detect abnormal forms of PrP in the neural tissues of the chicken. Even if it were assumed that there was successful uptake of infectivity into nervous tissues there are a number of possible reasons for the failure of the mammalian abnormal prion protein to initiate a disease process.

The three-dimensional structures of mammalian and chicken PrP^c^are quite similar although there is only \~30% sequence identity \[[@B43]-[@B45]\]. The C-terminal domain of mammalian PrP^c^forms a globular domain with a unique fold which consists of three α-helices and a short, anti-parallel β-sheet. Chicken PrP^c^has a number of additional structural elements not found in mammalian PrP^c^: a 3~10~helix between helices 2 and 3, an insertion between helices 2 and 3 which forms a flexibly disordered loop containing a glycosylation site and elongation of the N-terminal end of helix 3 \[[@B43]\]. The mechanism of conversion of PrP^c^to PrP^Sc^is not known but it is likely that it involves close range interactions between the two molecules. The additional structural elements present in chicken PrP^Sc^may inhibit or prevent this interaction. For example, changing the charge distribution at the protein\'s surface as occurs in the Gly200Lys mutation associated with familial Creutzfeldt-Jakob disease \[[@B46]\], which slows or prevents the propagation of PrP^d^.

The key difference between the structures of the PrP^c^and PrP^Sc^isoforms is the relative proportions of α-helices and β-sheets (reviewed in \[[@B47]\]). Dima and Thirumali \[[@B48]\] showed that the amino acid sequence of helix 2 of chicken PrP^c^has a higher propensity to form α-helices than the same region of mammalian (mouse) PrP^c^. This suggests that for chicken PrP^c^the transition from α-helix to β-sheet may not occur as readily as it does in mammals, or may not occur at all. Therefore, even if bovine PrP^Sc^was able to engage in close range interactions with chicken PrP^c^, it may not be able to induce the structural transformation which is necessary for formation of chicken PrP^Sc^.

Even assuming successful conversion of chicken PrP^c^into PrP^Sc^there is evidence that it lacks key metal-binding sites which may render it weakly- or non-pathogenic \[[@B49]\]. In mammalian PrP^c^there is a high-affinity copper-binding site located around His96 \[[@B50]-[@B53]\]. This site was found to be highly conserved in mammals but absent in the non-mammalian species examined, including chicken \[[@B49]\]. When copper or other divalent cations are absent or present at very low levels mammalian PrP^c^becomes more susceptible to proteolytic degradation and conversion efficiency is reduced (reviewed in \[[@B54]\]). If the affinity of chicken PrP^c^for copper is lower than in mammals it follows that chicken PrP^Sc^would be more susceptible to proteolytic degradation.

Although in the present study the experimental models used involved same species sub-passage and wild type mouse tissue assay after primary exposure to the BSE agent, it is possible that the chicken, or other avian species, are susceptible to other TSE agents after parenteral exposure. In a study where chickens were intravenously inoculated with a TME agent passaged in mink \[[@B55]\] putatively small amounts of infectivity were recovered by mink bioassay from chicken lymphoreticular tissues sampled at 30 and 148 days p.i. but the chickens did not show any neurological signs or pathological changes in the brain. No other diagnostic studies of the chickens\' tissues were performed. It is unclear whether this observation was related to uptake and persistence of inoculum, or replication of agent in the tissues.

Conclusion
==========

The present study addressed only the potential for the development of disease in the domestic chicken due to the BSE agent after parenteral or *per os*administration. Questions as to the possibilities of the uptake of inoculum into cells and whether infection can occur with a resultant sub-clinical state from exposure to TSE agents requires different approaches and highly sensitive species-specific immunochemical techniques, although the negative results of sub-passage experiments conducted in this study do not suggest establishment or persistence of infectivity in the donor tissues. The sequence of avian PrP is highly conserved among the avian species which have been tested and which are used for food, including pigeon \[[@B56]\], duck \[[@B57]\], quail \[[@B56]\] and peacock \[[@B57]\]. It is therefore unlikely that BSE could be successfully transmitted to these species.
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###### Additional file 1

**Female chicken, number 979, at 1270 days post parenteral inoculation (primary exposure study)**. It is first seen feeding from a trough (time 8:40 is displayed in the left bottom corner of the clip). It then retreats with its eyes closed and appears to sleep, sitting down with its head resting on the side of the trough. At 8:44, it wakes up, moves its head and gets up before feeding again from the trough.

###### 

Click here for file

###### Additional file 2

**Female chicken, number 980, at 1256 days post parenteral inoculation (primary exposure study)**. This chicken has difficulty maintaining balance as can be seen when it is pushed to the side or encouraged to move. It is generally reluctant to walk and has a tendency to stand with flexed intertarsal joints. By comparison, chicken 989, which was at the same time point post inoculation when filmed and is shown in the overlaid video clip, walks without difficulty and stands upright.

###### 

Click here for file
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